



## Nico Van Hoecke

Head of International Commercial

Nico leads Organon International, which covers all our markets outside the US. The OGN International team is focused on driving and accelerating growth across Organon's global footprint, ensuring we achieve our strategic enterprise and commercial objectives and priorities.

Nico has over two decades of experience in commercial management and finance as well as extensive expertise in supporting and growing organizations and business across the world. His most recent role at Organon was Europe Canada region president.

Nico started his career at MSD in Finance, taking on increased responsibilities over the years, including Finance Director for the Belgium, Netherlands, and Luxemburg cluster and Finance Director for Central and Eastern Europe. He later served as Regional Finance Lead for Eastern Europe Middle East and Africa and Business & Commercial Operations Lead for the same region.

Nico was also the Regional President for EEMEA at MSD, where he led the human health business across more than 70 countries, managing a team of over 1,700 staff. Under his management, the EEMEA region significantly changed its business trajectory, providing sustainable growth against a backdrop of unprecedented times and circumstances. Prior to this role, he led the Finance Organization for MSD's Emerging Markets, overseeing the finance departments of all countries in Latin America, EEMEA and Asia Pacific. Before joining MSD, he was an External Auditor with Deloitte Touche.

Nico has a Master's degree in corporate income taxes and commercial sciences, specialty in accountancy and a Bachelor's degree in commercial sciences, all from EHSAL in Brussels.

---

### About Organon

[Organon](#) is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon's diverse portfolio offers over 70 medicines and products in women's health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon's current products, the company invests in innovative solutions and research to drive future growth opportunities in women's health and biosimilars. Organon is also pursuing opportunities to collaborate with biopharmaceutical partners and innovators who look to commercialize their products by leveraging Organon's scale and agile presence in fast growing international markets. Organon has geographic scope with significant reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey. For more information, visit <http://www.organon.com> and connect with us on [LinkedIn](#), [Instagram](#), [X \(formerly known as Twitter\)](#) and [Facebook](#).